Stanley S Stylli
Overview
Explore the profile of Stanley S Stylli including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
56
Citations
1164
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Benn K, Yuan P, Chong H, Stylli S, Luwor R, French C
PLoS One
. 2025 Jan;
19(12):e0316845.
PMID: 39775361
[This corrects the article DOI: 10.1371/journal.pone.0309438.].
2.
Kwakowsky A, Chawdhary B, de Souza A, Meyer E, Kaye A, Green C, et al.
Int J Mol Sci
. 2023 Dec;
24(24).
PMID: 38139284
Multiple sclerosis (MS) is a neurodegenerative disease marked by chronic neuroinflammation thought to be mediated by the inflammasome pathway. Connexin 43 (Cx43) hemichannels contribute to the activation of the inflammasome...
3.
Dinevska M, Widodo S, Cook L, Stylli S, Ramsay R, Mantamadiotis T
Brain Behav Immun
. 2023 Dec;
116:140-149.
PMID: 38070619
Cancers of the central nervous system (CNS) are unique with respect to their tumor microenvironment. Such a status is due to immune-privilege and the cellular behaviors within a highly networked,...
4.
Whitehead C, Morokoff A, Kaye A, Drummond K, Mantamadiotis T, Stylli S
Exp Cell Res
. 2023 Aug;
431(1):113743.
PMID: 37591452
A critical challenge in the treatment of glioblastoma (GBM) is its highly invasive nature which promotes cell migration throughout the brain and hinders surgical resection and effective drug delivery. GBM...
5.
Whitehead C, Fang H, Su H, Morokoff A, Kaye A, Hanssen E, et al.
Cell Oncol (Dordr)
. 2023 Apr;
46(4):909-931.
PMID: 37014551
Purpose: The therapeutic efficacy of radiotherapy/temozolomide treatment for glioblastoma (GBM) is limited by the augmented invasiveness mediated by invadopodia activity of surviving GBM cells. As yet, however the underlying mechanisms...
6.
Dinevska M, Widodo S, Furst L, Cuzcano L, Fang Y, Mangiola S, et al.
Cell Oncol (Dordr)
. 2022 Dec;
46(3):589-602.
PMID: 36567397
Purpose: Tumor cells thrive by adapting to the signals in their microenvironment. To adapt, cancer cells activate signaling and transcriptional programs and migrate to establish micro-niches, in response to signals...
7.
Jones D, Whitehead C, Dinevska M, Widodo S, Furst L, Morokoff A, et al.
Mol Cell Biochem
. 2022 Oct;
478(6):1251-1267.
PMID: 36302993
Glioblastoma (GBM) is the most prevalent primary central nervous system tumour in adults. The lethality of GBM lies in its highly invasive, infiltrative, and neurologically destructive nature resulting in treatment...
8.
Campbell B, Gao Z, Corcoran N, Stylli S, Hovens C
Cancers (Basel)
. 2022 Oct;
14(19).
PMID: 36230886
Targeted therapies for cancers have improved primary tumor response rates, but concomitantly, brain metastases (BM) have become the most common brain tumors in adults and are associated with a dismal...
9.
Furst L, Atkins R, Dinevska M, Stylli S, Corcoran N, Hovens C, et al.
Methods Cell Biol
. 2022 Jul;
170:21-30.
PMID: 35811101
Cancer stem cells are defined as low-abundance, quiescent cells and are considered a major cellular source of tumor recurrence following therapy, which identifies these cells as important therapeutic targets for...
10.
Ma C, Nguyen H, Jones J, Stylli S, Whitehead C, Paradiso L, et al.
Int J Mol Sci
. 2022 Mar;
23(5).
PMID: 35269915
Glioblastoma is the most aggressive brain tumour with short survival, partly due to resistance to conventional therapy. Glioma stem cells (GSC) are likely to be involved in treatment resistance, by...